Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?
Authors:
- 25 August 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 22 (10) , 1415-1416
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNeuro-Oncology, 2020
- Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade GliomasCancer Cell, 2020
- Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialThe Lancet Oncology, 2019
- The molecular landscape of glioma in patients with Neurofibromatosis 1Nature Medicine, 2018